Fruquintinib plus sintilimab significantly improved PFS in advanced RCC patients compared to axitinib or everolimus, with a median PFS of 22.21 months versus 6.90 months. The combination therapy ...
And the standout bats they rely on the most — Christian Yelich, William Contreras, Brice Turang and Jackson Chourio — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback